...of the MC4R, a melanocortin receptor. ChemoCentryx plots path forward following Phase II miss in C3 glomerulopathy ChemoCentryx Inc....
...progression-free survival in September 2019.TARGETSANG2 (ANGPT2) – Angiopoietin 2C5AR1 (C5AR; CD88) – Complement receptor 5A BC Staff ChemoCentryx Inc....

...GenSight Biologics S.A. (Euronext:SIGHT); and avacopan from Vifor Fresenius Medical Care Renal Pharma Ltd. and ChemoCentryx Inc....
...Complement receptor 5A BC Staff LUMEVOQ (GS010, RAAV2/2_ND4) Avacopan (CCX168, C5aR inhibitor) JW Therapeutics Co. Ltd. GenSight Biologics S.A. Vifor Pharma Ltd. ChemoCentryx Inc. Fountain...

...the Northern District of West Virginia (see “More Pressure on Biogen's Pipeline”).July PDUFA date for ChemoCentryx...
...million in series A funding. TARGETSC5a – Complement 5a BC Staff Tecfidera, dimethyl fumarate (bg-12, BG00012) Avacopan (CCX168, C5aR inhibitor) Biogen ChemoCentryx Inc. Amytrx...

...as CSO, succeeding interim CSO David Spellmeyer. Singh was SVP of research and pharmaceutics at ChemoCentryx Inc....

...not respond to inquiries regarding financial terms. The company’s stock fell $5.98 to $68.65 Thursday. ChemoCentryx Inc....
...and inflammatory diseases company’s Wednesday close of $60.25, when it proposed the offering after hours. ChemoCentryx’s...
...NASDAQ:IMUX), which raised $25 million Wednesday. Elizabeth S. Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx Inc. Fate...

...ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius...

...such as Karuna Therapeutics Inc. (NASDAQ:KRTX), Myovant Sciences Inc. (NASDAQ:MYOV), Axsome Therapeutics Inc. (NASDAQ:AXSM) and ChemoCentryx Inc....
...Quintuples in Value” ; “Big Gain for Myovant” ; “Migraine Readout for Surging Axsome” ; “ChemoCentryx’s...

...to standard-of-care therapy in a Phase III trial to treat a rare form of vasculitis. ChemoCentryx Inc....
...cancer (see "Karuna Clears Bar" ; "Big Gain for Myovant" ). After market hours Monday, ChemoCentryx...
...improvements in kidney function and quality-of-life metrics. The study's results are to be included in ChemoCentryx's...

...Poised for Fresh Infusion of Hemoglobin-based Endpoints" ). ChemoCentryx soars on Phase III vasculitis data ChemoCentryx Inc....
...to reductions in glucocorticoid-related toxicity, improvements in kidney function and improvements in quality of life. ChemoCentryx...
...PDUFA date. Elizabeth S. Eaton, Staff Writer voxelotor (GBT440) Xtandi, enzalutamide (mdv3100, p-INN) Avacopan (CCX168, C5aR inhibitor) LJPC-401 Global Blood Therapeutics Inc. ChemoCentryx Inc. Astellas...

...heat-activated liposome Treat newly diagnosed, intermediate stage hepatocellular carcinoma (HCC) Phase III interim data 2H19 ChemoCentryx Inc....